murepavadin
Murepavadin (POL7080) is a Pseudomonas specific peptidomimetic antibiotic. It is a synthetic cyclic beta hairpin peptidomimetic based on the cationic antimicrobial peptide protegrin I (PG-1) and the first example of an outer membrane protein-targeting antibiotic class with a novel, nonlytic mechanism of action, highly active and selective against the protein transporter LptD of Pseudomonas aeruginosa. In preclinical studies the compound was highly active on a broad panel of clinical isolates including multi-drug resistant Pseudomonas bacteria with outstanding in vivo efficacy in sepsis, lung, and thigh infection models. Intravenous murepavadin is in development for the treatment of bacterial hospital-acquired pneumonia and bacterial ventilator-associated pneumonia due to Pseudomonas aeruginosa. — Wikipedia
Clinical trial activity
9 trials · 6 clinical orgs · 0 marketing orgs
Earliest trial started Apr 1, 2013 (NCT02110459)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMurepavadin ↗
Also known as
- pol7080
- ro7033877
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03582007 | Phase 3 | Sep 30, 2018 | Polyphor Ltd. |
| NCT03409679 | Phase 3 | Mar 23, 2018 | Polyphor Ltd. |
| NCT02897869 | Phase 1 | Apr 1, 2016 | Polyphor Ltd. |
| NCT02165332 | Phase 1 | Jul 1, 2014 | Roche |
| NCT02156323 | Phase 1 | Jul 1, 2014 | Roche |
| NCT02165293 | Phase 1 | Jun 1, 2014 | Roche |
| NCT02096315 | Phase 2 | Dec 1, 2013 | Polyphor Ltd., University of Barcelona, University of Edinburgh |
| NCT02096328 | Phase 2 | Oct 1, 2013 | Polyphor Ltd., University of Athens, University of Barcelona |
| NCT02110459 | Phase 1 | Apr 1, 2013 | CRS Clinical Research Services Kiel GmbH, Polyphor Ltd. |
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Polyphor Ltd. | For profit | 6 | 6 | 3 | 2013 |
| Roche | For profit | 3 | 3 | 1 | 2014 |
| University of Barcelona | Academic/Hospital | 2 | 0 | 1 | 2013 |
| CRS Clinical Research Services Kiel GmbH | For profit | 1 | 0 | 1 | 2013 |
| University of Athens | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of Edinburgh | Academic/Hospital | 1 | 0 | 1 | 2013 |